Institution
University of Milan
Education•Milan, Italy•
About: University of Milan is a education organization based out in Milan, Italy. It is known for research contribution in the topics: Population & Medicine. The organization has 58413 authors who have published 139784 publications receiving 4636354 citations. The organization is also known as: Università degli Studi di Milano & Statale.
Topics: Population, Medicine, Cancer, Blood pressure, Transplantation
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; Department of Head and Neck Oncology, Gustave Roussy, Villejuif; Université Paris Saclay, Villeroy-sur-Sierre, France; and Department of Nuclear Medicine and Endocrine Oncological Sciences and Public Health, University of Brescia.
472 citations
••
TL;DR: The multifaceted response to phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction includes improvement in pulmonary pressure and vasomotility, RV function and dimension, left ventricular relaxation and distensibility (structural changes and/or ventricular interdependence), and lung interstitial water metabolism.
Abstract: Background—The prevalence of heart failure with preserved ejection fraction is increasing. The prognosis worsens with pulmonary hypertension and right ventricular (RV) failure development. We targeted pulmonary hypertension and RV burden with the phosphodiesterase-5 inhibitor sildenafil. Methods and Results—Forty-four patients with heart failure with preserved ejection fraction (heart failure signs and symptoms, diastolic dysfunction, ejection fraction 50%, and pulmonary artery systolic pressure 40 mm Hg) were randomly assigned to placebo or sildenafil (50 mg thrice per day). At 6 months, there was no improvement with placebo, but sildenafil mediated significant improvements in mean pulmonary artery pressure (42.013.0%) and RV function, as suggested by leftward shift of the RV Frank-Starling relationship, increased tricuspid annular systolic excursion (69.019.0%) and ejection rate (17.08.3%), and reduced right atrial pressure (54.07.2%). These effects may have resulted from changes within the lung (reduced lung water content and improved alveolar-capillary gas conductance, 15.84.5%), the pulmonary vasculature (arteriolar resistance, 71.08.2%), and left-sided cardiac function (wedge pulmonary pressure, 15.73.1%; cardiac index, 6.00.9%; deceleration time, 13.01.9%; isovolumic relaxation time, 14.01.7%; septal mitral annulus velocity, 76.49.2%). Results were similar at 12 months. Conclusions—The multifaceted response to phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction includes improvement in pulmonary pressure and vasomotility, RV function and dimension, left ventricular relaxation and distensibility (structural changes and/or ventricular interdependence), and lung interstitial water metabolism (wedge pulmonary pressure decrease improving hydrostatic balance and right atrial pressure reduction facilitating lung lymphatic drainage). These results enhance our understanding of heart failure with preserved ejection fraction and offer new directions for therapy. Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01156636. (Circulation. 2011;124:164-174.)
470 citations
••
University of Insubria1, Cambridge University Hospitals NHS Foundation Trust2, University of Milan3, University of Amsterdam4, University of Western Australia5, Helsinki University Central Hospital6, University of Hawaii7, Denver Health Medical Center8, Canberra Hospital9, Stavanger University Hospital10, Hebrew University of Jerusalem11, Radboud University Nijmegen12, Foothills Medical Centre13, University of Pittsburgh14, State University of Campinas15, Harborview Medical Center16, University of California, San Diego17, Sapienza University of Rome18, University of Parma19, University of Catania20, Immanuel Kant Baltic Federal University21, Tbilisi State Medical University22, New York Medical College23, United Arab Emirates University24, Universidad Nacional de Asunción25, University of Brescia26, University of Toronto27, John Hunter Hospital28, Virginia Commonwealth University29, Harvard University30, Linköping University31, Rambam Health Care Campus32
TL;DR: The 2020 WSES guidelines on AA aim to provide updated evidence-based statements and recommendations on each of the following topics: diagnosis, non-operative management for uncomplicated AA, timing of appendectomy and in-hospital delay, surgical treatment, and intra-operative grading of AA.
Abstract: Acute appendicitis (AA) is among the most common causes of acute abdominal pain. Diagnosis of AA is still challenging and some controversies on its management are still present among different settings and practice patterns worldwide. In July 2015, the World Society of Emergency Surgery (WSES) organized in Jerusalem the first consensus conference on the diagnosis and treatment of AA in adult patients with the intention of producing evidence-based guidelines. An updated consensus conference took place in Nijemegen in June 2019 and the guidelines have now been updated in order to provide evidence-based statements and recommendations in keeping with varying clinical practice: use of clinical scores and imaging in diagnosing AA, indications and timing for surgery, use of non-operative management and antibiotics, laparoscopy and surgical techniques, intra-operative scoring, and peri-operative antibiotic therapy. This executive manuscript summarizes the WSES guidelines for the diagnosis and treatment of AA. Literature search has been updated up to 2019 and statements and recommendations have been developed according to the GRADE methodology. The statements were voted, eventually modified, and finally approved by the participants to the consensus conference and by the board of co-authors, using a Delphi methodology for voting whenever there was controversy on a statement or a recommendation. Several tables highlighting the research topics and questions, search syntaxes, and the statements and the WSES evidence-based recommendations are provided. Finally, two different practical clinical algorithms are provided in the form of a flow chart for both adults and pediatric (< 16 years old) patients. The 2020 WSES guidelines on AA aim to provide updated evidence-based statements and recommendations on each of the following topics: (1) diagnosis, (2) non-operative management for uncomplicated AA, (3) timing of appendectomy and in-hospital delay, (4) surgical treatment, (5) intra-operative grading of AA, (6) ,management of perforated AA with phlegmon or abscess, and (7) peri-operative antibiotic therapy.
470 citations
••
TL;DR: One important message to remember is that whenever a patient has evidence of a pituitary tumor, a serum T4 and TSH level must be obtained, and the dramatic reduction in pituitsary size and resolution of endocrine dysfunction with thyroid hormone is gratifying.
Abstract: I. Introduction The term “TSH-secreting pituitary tumors” includes two opposite clinical conditions: true thyrotroph neoplasia that results in secondary hyperthyroidism, also called “central hyperthyroidism,” and pituitary hyperplasia resulting from longstanding primary hypothyroidism. The latter condition was first recognized 145 yr ago (1), while the former was not clearly identified until the RIA era (2–8). However, in the 1950s and 1960s, while it became clear that Graves' disease was not caused by hyperpituitarism (9, 10), scattered reports suggested a possible association between pituitary tumors and hyperthyroidism (11–15), although no measurement of TSH levels was available during this time. The first case of TSH-secreting pituitary adenoma (TSH-oma) was documented in 1960 by measuring serum TSH levels with a bioassay (16). In 1970, Hamilton et al. (17) reported the first case of TSH-oma proved by a RIA that was much more sensitive and specific than the previously used bioassays. Classically, TSH-...
470 citations
••
TL;DR: Evidence suggesting a possible involvement of oxidative alterations of glutamate transporters in specific pathologies, including amyotrophic lateral sclerosis, Alzheimer's disease, brain trauma and ischaemia is reviewed.
470 citations
Authors
Showing all 58902 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yi Cui | 220 | 1015 | 199725 |
Peter J. Barnes | 194 | 1530 | 166618 |
Thomas C. Südhof | 191 | 653 | 118007 |
Charles A. Dinarello | 190 | 1058 | 139668 |
Alberto Mantovani | 183 | 1397 | 163826 |
John J.V. McMurray | 178 | 1389 | 184502 |
Giuseppe Remuzzi | 172 | 1226 | 160440 |
Russel J. Reiter | 169 | 1646 | 121010 |
Jean Louis Vincent | 161 | 1667 | 163721 |
Tobin J. Marks | 159 | 1621 | 111604 |
Tomas Hökfelt | 158 | 1033 | 95979 |
José Baselga | 156 | 707 | 122498 |
Naveed Sattar | 155 | 1326 | 116368 |
Silvia Franceschi | 155 | 1340 | 112504 |
Frederik Barkhof | 154 | 1449 | 104982 |